Arbor Biotechnologies

aid: arbor-biotechnologies
name: Arbor Biotechnologies
description: Arbor Biotechnologies is a next-generation gene editing company founded in 2016 by Feng Zhang, David Walt, David
  Scott and Winston Yan, and headquartered in Cambridge, Massachusetts. Its proprietary AI- and machine-learning-guided discovery
  engine has produced a toolbox of programmable DNA editors spanning knockdown, nuclease excision and compact reverse-transcriptase
  editing, aimed at functionally curative genomic medicines. The wholly-owned pipeline is focused on liver disease (ABO-101
  for primary hyperoxaluria type 1 and ABO-103, both LNP-delivered and partnered with Chiesi Group) and CNS disease (ABO-202,
  ABO-203 and ABO-204 for ALS, plus ABO-206, all AAV-delivered), alongside collaborative ex vivo cell therapy programs run
  with Vertex, Allogene, Edigene and Chiesi. Investors include ARCH Venture Partners, Ally Bridge Group, Temasek, TCG and
  the Samsung Life Science Fund. Arbor operates no product or developer API and publishes no developer portal, SDKs or API
  documentation; its corporate site does serve the standard WordPress REST API anonymously, which makes its press releases,
  site pages and taxonomies machine-readable.
url: https://raw.githubusercontent.com/api-evangelist/arbor-biotechnologies/refs/heads/main/apis.yml
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - authentication
  - security
  generated: '2026-09-03'
  method: derived
image: https://arbor.bio/wp-content/uploads/Transparent-Color-Logo-1.png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline-2026-07-31
x-sector: biotechnology
x-api-posture: no-product-api
specificationVersion: '0.23'
created: '2026-07-31'
modified: '2026-07-31'
tags:
- Company
- Biotechnology
- Gene Editing
- CRISPR
- Genomic Medicine
- Life Sciences
- Drug Development
- Clinical Trials
- Neurology
- Rare Disease
- Healthcare
- Private Company
apis:
- aid: arbor-biotechnologies:arbor-bio-website-wordpress-rest
  name: Arbor Biotechnologies Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Arbor Biotechnologies website at arbor.bio: the route index
    of the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://arbor.bio/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://arbor.bio/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Overlay
  url: overlays/arbor-biotechnologies-content-overlay.yaml
- type: DomainSecurity
  url: security/arbor-biotechnologies-domain-security.yml
- type: Website
  url: https://arbor.bio/
- type: Blog
  url: https://arbor.bio/stay-updated/
- type: BlogRSS
  url: https://arbor.bio/feed/
- type: About
  url: https://arbor.bio/who-we-are/
- type: Founders
  url: https://arbor.bio/who-we-are/founders/
- type: Leadership
  url: https://arbor.bio/who-we-are/leadership/
- type: Investors
  url: https://arbor.bio/who-we-are/investors/
- type: Partners
  url: https://arbor.bio/who-we-are/partnerships/
- type: Technology
  url: https://arbor.bio/what-we-do/
- type: Publications
  url: https://arbor.bio/what-we-do/scientific-publications/
- type: Pipeline
  url: https://arbor.bio/pipeline/
- type: ClinicalTrials
  url: https://arbor.bio/clinical-trial/
- type: Careers
  url: https://arbor.bio/inside-arbor/careers/
- type: Contact
  url: https://arbor.bio/get-in-touch/
- type: Support
  url: https://arbor.bio/get-in-touch/
- type: PrivacyPolicy
  url: https://arbor.bio/privacy-policy/
- type: TermsOfService
  url: https://arbor.bio/terms-of-use/
- type: SiteMap
  url: https://arbor.bio/site-map/
- type: LinkedIn
  url: https://www.linkedin.com/company/arborbio
- type: Twitter
  url: https://twitter.com/arbortx
- type: SecondaryMarket
  url: https://forgeglobal.com/arbor-biotechnologies_stock/
- type: AgentSkill
  url: skills/_index.yml
- type: LLMsTxt
  url: llms/arbor-biotechnologies-llms.txt
- type: Authentication
  url: authentication/arbor-biotechnologies-authentication.yml
- type: Conventions
  url: conventions/arbor-biotechnologies-conventions.yml
- type: ErrorCatalog
  url: errors/arbor-biotechnologies-problem-types.yml
- type: DataModel
  url: data-model/arbor-biotechnologies-data-model.yml
- type: Lifecycle
  url: lifecycle/arbor-biotechnologies-lifecycle.yml
- type: Conformance
  url: conformance/arbor-biotechnologies-conformance.yml
x-enrichment:
  date: '2026-07-31'
  status: enriched
  artifacts_added: 12
  pass: local-v1
  notes: No product API. Contract discovery probed arbor.bio and www.arbor.bio plus eight non-resolving subdomains (api, developer,
    docs, status, trust, mcp, app, portal) for OpenAPI, GraphQL, MCP tools/list, A2A agent cards and the full /.well-known/
    set — all 404 or NXDOMAIN. The one real machine-readable contract found is the site's anonymous WordPress REST API at
    https://arbor.bio/wp-json (18 namespaces, 341 declared routes); an OpenAPI 3.1 covering 21 individually verified anonymous
    read operations was derived from that live route index. No packages, MCP server, agent card, OAuth scopes, vulnerability-disclosure
    programme or trust center exist; those artifacts were deliberately not written rather than stubbed, and no WellKnown pointer
    was emitted because every /.well-known/ probe returned 404.